Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(12): 1520-1541, 2017 12.
Article
in En
| MEDLINE
| ID: mdl-29223990
ABSTRACT
Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myeloid Cells
/
Intercellular Signaling Peptides and Proteins
/
Chemotherapy-Induced Febrile Neutropenia
/
Antineoplastic Agents
Type of study:
Etiology_studies
/
Guideline
/
Incidence_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
J Natl Compr Canc Netw
Year:
2017
Document type:
Article